OBJECTIVE: To assess clinical practice of intermittent hormone therapy (IHT) among urologists members of the French Association of Urology.
METHODS: Internet-based observational survey evaluating IHT modalities in prostate cancer using questionnaire sent to 941 urologists.
RESULTS: Two hundred and sixty nine urologists participated in the survey (response rate 28.6 %) including 90.3 % prescribing IHT. The main reasons for IHT were improvement of quality of life in 94.2 %, clinical tolerance in 73.7 %, decreased costs and oncological equivalence in 44 %. The indications were localized prostate cancer (low risk 22.6 %, intermediate 19.8 %, high 14 %), locally advanced (59.7 %), metastatic (63.4 %), biochemical recurrence after local treatment (prostatectomy 62.1 %, radiotherapy 73.7 %). A PSA < 2 ng/mL was considered as the threshold for androgen deprivation therapy break in 70 % of cases regardless of the IHT indication. The PSA threshold selected for the re-initiation of treatment was 4 ng/mL in 37.9 % and 10 ng/mL in 36.6 % of cases. The cycle of IHT was 6 months in 60 % of cases.
CONCLUSION: This survey provided a snapshot of the practice of IHT in France. Even in the absence of level of evidence 1 trials in the literature, most urologists used IHT in their clinical practice, for many indications, especially in case of biochemical recurrence after local treatment.
Written by:
Salomon L, Ploussard G, Coloby P, Kouri G, Lebret T, Méjean A, Prunet D, Soulié M. Are you the author?
CHU Henri-Mondor, 51, avenue du Maréchal-de-Tassigny, 94010 Créteil, France; CHU Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Centre hospitalier René Dubos, 6, avenue de l'Ile-de-France, 95300 Pontoise, France; Centre hospitalier Périgueux, 80, avenue Georges-Pompidou, 24019 Périgueux cedex, France; Hôpital Foch, 40, rue Worth, 92151 Suresnes, France; HEGP, 20, rue Leblanc, 75015 Paris, France; Clinique Pasteur, 222, route de Rochefort, 17200 Royan, France; CHU Rangueil, 1, avenue du Pr Jean Poulhès, TSA 50032, 31059 Toulouse, France.
Reference: Prog Urol. 2014 May;24(6):367-73.
doi: 10.1016/j.purol.2013.10.007
PubMed Abstract
PMID: 24821560
Article in French.
UroToday.com Prostate Cancer Section
